Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOBA: Phase 3 Study of Infigratinib (KK8398) in Pediatric Achondroplasia
jRCT2031240562Phase 3Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infigratinib in achondroplasia (ACH), sponsored by Kyowa Kirin. Primary endpoint: Change from Baseline in annualized height velocity. Started Apr 2025; status: active, not recruiting.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2031240562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240562.